Curasight A/S presents at HC Andersen Capital & Nordea Markets Virtual Growth Days seminar - 9 December 2021
Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans at HC Andersen Capital & Nordea Markets Virtual Growth Days seminar.
The presentation will be webcasted live 09:00 – 09:15 (CET), Thursday 9 December 2021.
For more information and registration– please click here
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.